Survival benefit of statins in older patients with rectal cancer: A Swedish population-based cohort study

Kotti, Angeliki; Holmqvist, Annica; Albertsson, Maria; Sun, Xiao‐Feng

doi:10.1016/j.jgo.2019.01.011

Cited by 10 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While no conclusions may be drawn, we suggest that this could be the result of a possible effect of statin therapy on rectal carcinoma proliferation. Previous studies have also suggested that statin users show complete response to neoadjuvant chemoradiation compared with nonusers, which further justifies the use of this drug as part of the overall optimization process of patients with rectal cancer who are planned for surgery [35,36]. At this point, however, there is insufficient evidence to implement statin treatment for all patients diagnosed with rectal cancer.…”

Section: Discussionmentioning

confidence: 99%

Statin therapy and postoperative short‐term mortality after rectal cancer surgery

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Statin therapy and postoperative short‐term mortality after rectal cancer surgery

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These findings are similar to those of three previous epidemiological studies conducted in patients with CRC and T2D [ 11 , 26 , 45 ]. Studies concerning RC and statin use in nondiabetics have linked statin use with reduced postoperative mortality [ 46 ], improved response to neoadjuvant therapy [ 47 , 48 ] and improved overall and disease-specific survival [ 49 ]. A recent meta-analysis associated pre-diagnostic statin use with reduced CRC mortality and reduced overall recurrence, but not with overall progression-free survival, regardless of subsite [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study

et al. 2022

View full text Add to dashboard Cite

Metformin and statin use have been associated with an improved prognosis for colorectal cancer in persons with type 2 diabetes (T2D). Data regarding rectal cancer (RC) have been inconclusive; therefore, we investigated the issue with high-quality data and a robust study design. We identified 1271 eligible patients with T2D and incident RC between 1998 and 2011 from the Diabetes in Finland (FinDM) database. Cox models were fitted for cause-specific mortality rates to obtain adjusted estimates of the hazard ratios (HR) with 95% confidence intervals (CI) in relation to use of antidiabetic medication (ADM) and statins before the RC diagnosis and for post-diagnostic use in a time-dependent exposure manner. No sufficient evidence was found for either pre- or post-diagnostic metformin use and RC mortality (HR 0.96, 95% CI 0.67–1.38, and 0.70, 95% CI 0.45–1.10, respectively) when compared to other oral ADMs. Both pre- and post-diagnostic statin use appeared to be inversely associated with mortality from RC (HR 0.77 95% CI 0.63–0.94, and 0.57, 95% CI 0.42–0.78, respectively). Our study was inconclusive as to the association of metformin use with the prognosis of RC, but statin use was found to predict reduced mortality, both from RC and from other causes of death in persons with T2D.

show abstract

“…Few prior studies assessing the long-term effects of statin therapy have addressed patients with rectal cancer alone. In a regional Swedish population-based analysis, statin use at the time of rectal cancer diagnosis was significantly associated with improved all-cause, cancer-specific, and disease-free survival for patients aged 70 years or older [ 26 ]. Multiple retrospective cohort studies have demonstrated higher rates of pathologically complete responses to neoadjuvant chemoradiation following statin therapy, further supporting the use of statins as part of the concatenated treatment optimization of patients with rectal cancer [ 27 , 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Statin Use and Long-Term Mortality after Rectal Cancer Surgery

Pourlotfi

Bass

Hulme

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: The current study aimed to assess the association between regular statin therapy and postoperative long-term all-cause and cancer-specific mortality following curative surgery for rectal cancer. The hypothesis was that statin exposure would be associated with better survival. Methods: Patients with stage I–III rectal cancer undergoing surgical resection with curative intent were extracted from the nationwide, prospectively collected, Swedish Colorectal Cancer Register (SCRCR) for the period from January 2007 and October 2016. Patients were defined as having ongoing statin therapy if they had filled a statin prescription within 12 months before and after surgery. Cox proportional hazards models were employed to investigate the association between statin use and postoperative five-year all-cause and cancer-specific mortality. Results: The cohort consisted of 10,743 patients who underwent a surgical resection with curative intent for rectal cancer. Twenty-six percent (n = 2797) were classified as having ongoing statin therapy. Statin users had a considerably decreased risk of all-cause (adjusted hazard ratio (HR) 0.66, 95% confidence interval (CI): 0.60–0.73, p < 0.001) and cancer-specific (adjusted HR 0.60, 95% CI: 0.47–0.75, p < 0.001) mortality up to five years following surgery. Conclusions: Statin use was associated with a lower risk of both all-cause and rectal cancer-specific mortality following curative surgical resections for rectal cancer. The findings should be confirmed in future prospective clinical trials.

show abstract

Survival benefit of statins in older patients with rectal cancer: A Swedish population-based cohort study

Cited by 10 publications

References 33 publications

Statin therapy and postoperative short‐term mortality after rectal cancer surgery

Statin therapy and postoperative short‐term mortality after rectal cancer surgery

The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study

Statin Use and Long-Term Mortality after Rectal Cancer Surgery

Contact Info

Product

Resources

About